Suzhou Ribo Life Science Income Statement

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2019	FY 2018
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018
Revenue	148.51	142.63	0.04	-	-
Revenue Growth (YoY)	4.13%	324052.27%	-	-	-
Cost of Revenue	13.48	26.98	25.03	1.96	2.44
Gross Profit	135.03	115.65	-24.98	-1.96	-2.44
Selling, General & Admin	119.46	93.49	81.45	25.43	18.53
Research & Development	280.46	280.37	315.76	112.68	90.48
Other Operating Expenses	14.36	0.05	0.01	0.13	0.05
Operating Expenses	414.37	373.99	397.51	138.43	109.12
Operating Income	-279.34	-258.34	-422.49	-140.39	-111.57
Interest Expense	-21.44	-20.4	-19.19	-1.95	-
Interest & Investment Income	2.24	2.52	4.91	1.05	2.86
Earnings From Equity Investments	-	-	-0.02	-	-3.89
Currency Exchange Gain (Loss)	-	2.35	0.18	0.23	0.26
Other Non Operating Income (Expenses)	13.98	16.82	25.73	-0.03	-0.02
EBT Excluding Unusual Items	-284.56	-257.05	-410.88	-141.08	-112.36
Gain (Loss) on Sale of Investments	-	-	0.24	-	-
Gain (Loss) on Sale of Assets	-	-	-	-0	-0.01
Asset Writedown	-	-	-26.51	-0.02	-0
Other Unusual Items	-	-	-	6.44	13.1
Pretax Income	-284.56	-257.05	-437.15	-134.67	-99.27
Income Tax Expense	3.9	24.45	0.15	-	-
Earnings From Continuing Operations	-288.45	-281.49	-437.3	-134.67	-99.27
Minority Interest in Earnings	10.4	11.34	8.95	0.31	0.61
Net Income	-278.06	-270.15	-428.35	-134.35	-98.66
Net Income to Common	-278.06	-270.15	-428.35	-134.35	-98.66
Shares Outstanding (Basic)	132	129	128	30	27
Shares Outstanding (Diluted)	132	129	128	30	27
Shares Change (YoY)	2.55%	0.19%	330.71%	10.22%	10.39%
EPS (Basic)	-2.11	-2.10	-3.34	-4.51	-3.65
EPS (Diluted)	-2.11	-2.10	-3.34	-4.51	-3.65
Free Cash Flow	-	-84.04	-327.53	-144.63	-111.39
Free Cash Flow Per Share	-	-0.65	-2.55	-4.85	-4.12
Gross Margin	90.93%	81.09%	-	-	-
Operating Margin	-188.09%	-181.13%	-960211.36%	-	-
Profit Margin	-187.23%	-189.41%	-973520.46%	-	-
Free Cash Flow Margin	-	-58.92%	-744395.46%	-	-
EBITDA	-240.5	-219.49	-379.43	-121.55	-95.33
EBITDA Margin	-161.94%	-153.89%	-	-	-
D&A For EBITDA	38.84	38.84	43.06	18.83	16.24
EBIT	-279.34	-258.34	-422.49	-140.39	-111.57
EBIT Margin	-188.09%	-181.13%	-	-	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.